Novartis Q2 Earnings Preview: Positive Fundamental Trends Should Continue

Seeking Alpha, TradingView As I covered in the first quarter earnings review article, the reported numbers should remain unfavorable due to the spinoff of the generic unit Sandoz last year. We should look at the adjusted numbers of the remaining core business (continuing operations), which continue to look strong. Seeking Alpha The key performance drivers will be the innovative growth products, and Entresto: The core EPS consensus is $1.85, up 0.9% Y/Y in reported numbers, and an 11% increase if we look at ...